Profound Medical Corp News - PRN

FeaturedNorth Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton

Profound Medical to Participate in A.G.P.’s Virtual Healthcare Conference

TORONTO, May 18, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Profound Medical Annual and Special Meeting of Shareholders Voting Results

TORONTO, May 17, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the...

Profound Medical Announces First Quarter 2023 Financial Results

TORONTO, May 10, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting

– Presentations reinforce the safety, efficacy and durability of the TULSA procedure, further supporting its...

Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to Follow

TORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Profound Medical Announces Fourth Quarter and Full Year 2022 Financial Results

TORONTO, March 07, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Profound Medical to Present at the 43rd Annual Cowen Health Care Conference

TORONTO, March 01, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Profound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to Follow

TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Profound Medical to Present at the 2022 Jefferies London Healthcare Conference

TORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Profound Medical Announces Third Quarter 2022 Financial Results

TORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow

TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Four Year Follow-Up Data from Profound Medical’s TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO® of Men with Localized Prostate Cancer

TORONTO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Profound Medical Announces Changes to its Commercial Organization to Support Continued Growth

TORONTO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Profound Medical Corp (PRN)

Empower your portfolio: Real-time discussions and actionable trading ideas.

PRN News

FeaturedNorth Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton

Profound Medical to Participate in A.G.P.’s Virtual Healthcare Conference

Profound Medical Annual and Special Meeting of Shareholders Voting Results

Profound Medical Announces First Quarter 2023 Financial Results

TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting

Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to Follow

Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference

Profound Medical Announces Fourth Quarter and Full Year 2022 Financial Results

Profound Medical to Present at the 43rd Annual Cowen Health Care Conference

Profound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to Follow

Profound Medical to Present at the 2022 Jefferies London Healthcare Conference

Profound Medical Announces Third Quarter 2022 Financial Results

Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow

Four Year Follow-Up Data from Profound Medical’s TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO® of Men with Localized Prostate Cancer

Profound Medical Announces Changes to its Commercial Organization to Support Continued Growth

PRN Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Profound Medical Corp (PRN) News

Profound Medical Corp (PRN)

Empower your portfolio: Real-time discussions and actionable trading ideas.

PRN News

FeaturedNorth Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton

Profound Medical to Participate in A.G.P.’s Virtual Healthcare Conference

Profound Medical Annual and Special Meeting of Shareholders Voting Results

Profound Medical Announces First Quarter 2023 Financial Results

TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting

Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to Follow

Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference

Profound Medical Announces Fourth Quarter and Full Year 2022 Financial Results

Profound Medical to Present at the 43rd Annual Cowen Health Care Conference

Profound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to Follow

Profound Medical to Present at the 2022 Jefferies London Healthcare Conference

Profound Medical Announces Third Quarter 2022 Financial Results

Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow

Four Year Follow-Up Data from Profound Medical’s TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO® of Men with Localized Prostate Cancer

Profound Medical Announces Changes to its Commercial Organization to Support Continued Growth

PRN Discussion

Your Recent History